Michel Detheux - Dec 5, 2023 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Chief Executive Officer
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
Stock symbol
ITOS
Transactions as of
Dec 5, 2023
Transactions value $
$0
Form type
4
Date filed
12/7/2023, 08:20 PM
Previous filing
Mar 10, 2023
Next filing
Mar 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITOS Common Stock Award $0 +30K +103.8% $0.00 58.9K Dec 5, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. All of the shares of common stock underlying such RSUs will vest on December 5, 2025, subject to the Reporting Person's continued service to the Issuer.
F2 Amount of Securities Beneficially Owned includes 1,445 and 1,195 shares purchased under the Company's 2020 Employee Stock Purchase Plan on November 30, 2022 and May 31, 2023, respectively.